Type I interferon signature in systemic lupus erythematosus.
Isr Med Assoc J
; 16(4): 246-9, 2014 Apr.
Article
em En
| MEDLINE
| ID: mdl-24834763
ABSTRACT
Type I interferons (IFN) are primarily regarded as an inhibitor of viral replication. However, type I IFN, mainly IFNalpha, plays a major role in activation of both the innate and adaptive immune systems. Systemic lupus erythematosus (SLE) is a chronic, multi-systemic, inflammatory autoimmune disease with undefined etiology. SLE is characterized by dysregulation of both the innate and the adaptive immune systems. An increased expression of type I IFN-regulated genes, termed IFN signature, has been reported in patients with SLE. We review here the role of IFNalpha in the pathogenesis and course of SLE and the possible role of IFNalpha inhibition as a novel treatment for lupus patients.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Interferon Tipo I
/
Regulação da Expressão Gênica
/
Lúpus Eritematoso Sistêmico
Limite:
Animals
/
Humans
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article